Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 express...

Descripción completa

Detalles Bibliográficos
Autores principales: Horesh, Adi, Pollack, Rena, Nechushtan, Hovav, Dresner-Pollak, Rivka, Neuman, Tzahi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149681/
https://www.ncbi.nlm.nih.gov/pubmed/37139142
http://dx.doi.org/10.3389/pore.2023.1610951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149681/
https://www.ncbi.nlm.nih.gov/pubmed/37139142
http://dx.doi.org/10.3389/pore.2023.1610951

Ejemplares similares